Company / Net Income
Vertex Pharmaceuticals Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
$4.0B
FY2025
5-year range
-$535.6M / $4.0B
FY2021-FY2025
Trend
+838.1%
vs FY2024
Sector context
#12 of 216
Health Care
What the data says
Net Income changed +838% YoY in FY2025, a notable deviation from the 9-year average annual change of +209%.
Based on SEC 10-K filings.
$4.0B in FY2025 with a 5-year CAGR of +7.8%. Top quartile in the Health Care sector.
Improved from $3.6B to $4.0B over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- +6.0%
- 5-Year CAGR
- +7.8%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 216This company $4.0B Sector average $454.3M
▼
+770.2% above sector average
Key checks
Key Insights
- 5-year CAGR of +7.8%, indicating consistent growth.
- In FY2025, net income increased 838.1% year-over-year.
- Ranks #12 out of 216 companies in the Health Care sector.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0B | +838.1% |
| FY2024 | -$535.6M | -114.8% |
| FY2023 | $3.6B | +9.0% |
| FY2022 | $3.3B | +41.8% |
| FY2021 | $2.3B | -13.6% |
| FY2020 | $2.7B | +130.4% |
| FY2019 | $1.2B | -43.9% |
| FY2018 | $2.1B | +695.8% |
| FY2017 | $263.5M | +335.1% |
| FY2016 | -$112.1M | +79.9% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026